Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Phenobarbital sodium
Drug ID BADD_D01753
Description A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Indications and Usage For the treatment of all types of seizures except absence seizures.
Marketing Status approved; investigational
ATC Code N03AA02
DrugBank ID DB01174
KEGG ID D00701
MeSH ID D010634
PubChem ID 23674889
TTD Drug ID D0Y7RW
NDC Product Code 0792-0004; 63629-2007; 75834-288; 75834-289; 66064-1017; 72162-1330; 62756-301; 63629-1998; 63629-2008; 0641-0476; 65319-1465; 72162-1329; 42494-441; 0641-0477; 54288-136; 65319-1013; 42494-442; 63629-1997; 54288-137
UNII SW9M9BB5K3
Synonyms Phenobarbital | Phenylbarbital | Phenylethylbarbituric Acid | Acid, Phenylethylbarbituric | Phenemal | Phenobarbitone | Hysteps | Phenobarbital Sodium | Sodium, Phenobarbital | Phenobarbital, Monosodium Salt | Monosodium Salt Phenobarbital | Luminal | Gardenal
Chemical Information
Molecular Formula C12H11N2NaO3
CAS Registry Number 57-30-7
SMILES CCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.012--
Anaemia megaloblastic14.12.01.003; 01.03.02.003--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Apnoea22.02.01.001--
Ataxia08.01.02.004; 17.02.02.001--
Bradycardia02.03.02.002--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Depressed level of consciousness17.02.04.002--
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Hypoventilation22.02.01.007--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia17.15.03.002; 19.02.01.002--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Toxic epidermal necrolysis12.03.01.015; 11.07.01.006; 10.01.01.006; 23.03.01.008--
The 1th Page    1 2    Next   Last    Total 2 Pages